/header_300040.jpg
Home » Media » Press Releases
Triptorelin – Trelstar® – Decapeptyl® - Pamorelin®
 Date  Article Title
15 May 2012 Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland - A drug treatment for prostate cancer and endometriosis
04 Feb 2010 Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
13 Oct 2009 Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of locally advanced or metastatic prostate cancer
11 May 2009 Debiopharm and Mepha sign distribution agreement for Pamorelin® LA 1-3- and 6-month formulations - a new treatment for prostate cancer patients in Switzerland -
31 Mar 2009 Bachem and Debiopharm sign follow-up contract for long-term supply of Triptorelin Pamoate
14 Nov 2008 Debiopharm announces U.S. NDA filing of Trelstar® 6-month formulation for locally advanced or metastatic prostate cancer
25 Sep 2008 Debiopharm moves towards a new 6-month formulation of Decapeptyl® to further help prostate cancer patients
12 Feb 2008 Clinical Update – Decapeptyl®/Trelstar® 6-Month Formulation in Advanced Prostate Cancer
31 Oct 2007 Ipsen and Debiopharm extend their Agreement for the Exclusive Commercialization of Decapeptyl®
11 May 2005 Debiopharm announces marketing and supply agreement for Trelstar® in Canada
20 Dec 2004 Debiopharm S.A. and Rowfarma S. de R.L. de C.V. enter into an Exclusive Licensing Agreement in Mexico for two approved Urology and Endometriosis Products - Decapeptyl® Depot and Decapeptyl® LA
29 Sep 2004 Debiopharm and Watson Pharmaceuticals enter into an Exclusive Licensing Agreement for two approved urology products - Trelstar® DEPOT and Trelstar® LA
23 Mar 2004 Debiopharm´s Pamorelin Long Acting, Formulated Using Debio® PLGA Technology, receives Final Marketing Autorisation in Germany
02 Dec 2003 Debiopharm S.A. seeks New Partner to Commercialise Trelstar® (Triptorelin Pamoate) in the US, Canada and Mexico for the Treatment of Prostate Cancer
05 Jul 2001 Swiss drug developer Debiopharm announces FDA approval of Trelstar TM LA for therapeutic use
 

Latest News

Debiopharm on   Facebook  Linkedin